'Scotoma awareness' Training for Macular Degeneration

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UAB, Birmingham, AL
Macular Degeneration+3 More
'Scotoma awareness' Training - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight. Declines in vision are particularly common in older adults and thus increasing our understanding of how to cre- ate effective means of improving vision is also highly relevant to the mission of the NIA to support research on aging and the health and well-being of older people.

Eligible Conditions

  • Macular Degeneration
  • Low Vision

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Macular Degeneration

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Week 14
Change from Baseline Contrast Sensitivity after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline First saccade landing dispersion after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Fixation stability after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Latency of target acquisition after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Minimal print size from MNREAD task after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Percentage of trials that are useful after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Saccadic precision after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Saccadic re-referencing after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Visual Acuity after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline time-to-complete Trailmaking B subtest after completion of Training at approximately 6 weeks and 14 weeks

Trial Safety

Safety Progress

1 of 3

Other trials for Macular Degeneration

Trial Design

2 Treatment Groups

Condition 2 - Control Training
1 of 2
Condition 1 - 'Scotoma awareness' Training
1 of 2
Experimental Treatment

16 Total Participants · 2 Treatment Groups

Primary Treatment: 'Scotoma awareness' Training · No Placebo Group · N/A

Condition 2 - Control Training
Behavioral
Experimental Group · 1 Intervention: Control Training · Intervention Types: Behavioral
Condition 1 - 'Scotoma awareness' Training
Behavioral
Experimental Group · 1 Intervention: 'Scotoma awareness' Training · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Control Training
2013
N/A
~240

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Closest Location: UAB · Birmingham, AL
Photo of Birmingham 1Photo of Birmingham 2Photo of Birmingham 3
2011First Recorded Clinical Trial
3 TrialsResearching Macular Degeneration
28 CompletedClinical Trials

Who is running the clinical trial?

University of California, RiversideOTHER
21 Previous Clinical Trials
6,691 Total Patients Enrolled
2 Trials studying Macular Degeneration
180 Patients Enrolled for Macular Degeneration
University of Alabama at BirminghamLead Sponsor
1,400 Previous Clinical Trials
2,210,970 Total Patients Enrolled
4 Trials studying Macular Degeneration
233 Patients Enrolled for Macular Degeneration

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a visual acuity of 20/100 or worse in both eyes.
You have macular degeneration.
You have a light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (SLO, MAIA).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.